7:19 AM
May 20, 2019
 |  BC Innovations  |  Distillery Therapeutics

MAT2A identified as a target in solid and liquid cancers


INDICATION: Lung; leukemia; lymphoma; solid tumors

Cell and mouse studies suggest inhibiting MAT2A could help treat lung and other solid and liquid cancers. In a panel of human cancer cell lines, including glioblastoma, colorectal cancer, leukemia, lymphoma, melanoma and breast cancer, a tool compound MAT2A...

Read the full 212 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >